Ignite Creation Date:
2024-05-05 @ 11:11 PM
Last Modification Date:
2024-10-26 @ 10:30 AM
Study NCT ID:
NCT01276639
Status:
COMPLETED
Last Update Posted:
2014-09-19
First Post:
2011-01-12
Brief Title:
A One-Year Study To Evaluate The Effects And Safety Of CP-690550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 3 Randomized Double-Blind Placebo-Controlled Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this study is to compare the effects of CP-690550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis This one-year study will also evaluate the safety and tolerability of CP-690550 versus placebo
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None